{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(6)"],"submitter":["Wurtz NR"],"pubmed_abstract":["Formyl peptide receptor 2 (FPR2) agonists have shown efficacy in inflammatory-driven animal disease models and have the potential to treat a range of diseases. Many reported synthetic agonists contain a phenylurea, which appears to be necessary for activity in the reported chemotypes. We set out to find isosteres for the phenylurea and focused our efforts on heteroaryl rings. The wide range of potencies with heterocyclic isosteres demonstrates how electronic effects of the heteroatom placement impact molecular recognition. Herein, we report our discovery of benzimidazole and aminophenyloxadiazole FPR2 agonists with low nanomolar activity."],"journal":["ACS medicinal chemistry letters"],"pagination":["943-948"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9190041"],"repository":["biostudies-literature"],"pubmed_title":["Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists."],"pmcid":["PMC9190041"],"pubmed_authors":["Park H","Wexler RR","Kick EK","Hsu MY","Wurtz NR","Johnson JA","Madduri S","Galella MA","Baligar V","Abousleiman M","Cheney DL","Aulakh D","Ostrowski J","Lupisella JA","Viet A","Garcia RA","Dierks EA","Shirude PS"],"additional_accession":[]},"is_claimable":false,"name":"Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists.","description":"Formyl peptide receptor 2 (FPR2) agonists have shown efficacy in inflammatory-driven animal disease models and have the potential to treat a range of diseases. Many reported synthetic agonists contain a phenylurea, which appears to be necessary for activity in the reported chemotypes. We set out to find isosteres for the phenylurea and focused our efforts on heteroaryl rings. The wide range of potencies with heterocyclic isosteres demonstrates how electronic effects of the heteroatom placement impact molecular recognition. Herein, we report our discovery of benzimidazole and aminophenyloxadiazole FPR2 agonists with low nanomolar activity.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-04-27T02:22:23.311Z","creation":"2025-04-06T18:32:05.938Z"},"accession":"S-EPMC9190041","cross_references":{"pubmed":["35707160"],"doi":["10.1021/acsmedchemlett.2c00079"]}}